Sep 1, 2010 - In a study published this week by Majestic Research , almost 60% of neurologists expressed unaided concern about the side effects/safety of oral MS therapies in development, including NVS's Gilenia and MRK/EMD Serono's oral cladribine.
More...
(From Topix Neurology)